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ABSTRACT 
Cancer cells are more vulnerable to targeting during S-G2-M cell cycle phases due to common 
deregulations in cell cycle checkpoint mechanisms. Most common cancer drugs target 
processes in the S-G2-M phases, often causing negative effects on proliferating normal cells. 
On the other hand, several metabolic processes are deregulated in cancer, generating metabolic 
dependencies and exposing vulnerabilities specific to cancer cells. Therefore, deregulated 
metabolic processes in the S-G2-M phases potentially offer effective targeting strategy without 
harming normal cells. There are some studies reporting cyclic metabolic processes in 
synchronized cells, but a more systematic study of metabolism across cell cycle is lacking. 
The focus of this thesis is to trace metabolic events in G1 and S-G2-M phases, and identify 
metabolic enzymes that affect cancer cell proliferation using an approach that does not interfere 
with cell metabolism. Initially we developed a method for performing metabolomics in sorted 
cells, then applied this method on G1 and S-G2-M sorted normal and transformed cells. We 
mapped hundreds of metabolites and metabolic activities in G1 and S-G2-M phases, and 
identified arginase 2 (ARG2) enzyme as a potential target which reduced cancer cell 
proliferation. This study can be used as a resource of metabolism across the cell cycle. This 
project presents a large scale investigation of metabolism in G1 and S-G2-M phases, 
contributing to the understanding of the biology of metabolism across the cell cycle and reveals 
metabolic activities in the S-G2-M phases of cancer cells. This thesis is comprised of the 
following papers.  
In Paper I (Roci et al, 2016) we developed a method for performing metabolomics in sorted 
subpopulations combining Fluorescence Activated Cell Sorting (FACS) and Liquid 
Chromatography Mass Spectrometry (LC-MS). We evaluated relative metabolite abundance 
using peak areas and metabolic activities using isotope tracing. From benchmarking of sorted 
sampled with extraction from culture dish we found that isotope tracing is more robust and 
reflects the metabolism of cells in culture dish.  
In Paper II (manuscript) and Paper III (Roci et al, 2019) we mapped metabolism in G1 and 
S-G2-M phases and presented relative metabolite abundances and metabolic activities in these 
phases. Most metabolite abundances and 13C enrichment were constant showing that they are 
required throughout cell cycle. Some metabolic processes like ornithine synthesis, arginine 
uptake showed higher activities in the S-G2-M, while synthesis of some phosphorylated sugar 
metabolites was upregulated in G1 phase.  
In a follow-up study of the ornithine synthesizing enzyme, ARG2 presented in (Paper III), we 
found that silencing of ARG2 reduced cancer cell proliferation. Cancer cells synthesized 
ornithine only via ARG2, but normal cells used both ARG2 and the alternative pathway via 
Ornithine transferase (OAT). High ARG2 expression was correlated with ER negative and 
Basal breast cancer subtypes, and poor survival in these cancer types.   
In Paper IV (manuscript) we present a survey of choline metabolism by culturing several 
normal and transformed cell lines in 13C3-choline. Betaine was synthesized only in cancer cells 
and was not a methyl donor in any of the cell lines. The choline dehydrogenase (CHDH) 
enzyme, which synthesizes the precursor of betaine, was also expressed only in cancer cell 
lines, and caused an increase of G2-M phase cells when silenced. Besides, from untargeted 
analysis we found 122 peaks that were labeled from choline, including phosphatidylcholine 
synthesized in all cell lines, and other previously unknown peaks. 
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BACKGROUND 
1 INTRODUCTION 
Metabolism is the collection of biochemical processes that transform small molecules to form 
macromolecules and biomass in a cell. The life cycle of a mammalian cell, also called the 
cell cycle, is characterized by an increase in biomass (DNA and protein content), membrane 
surface and cell volume, all of which duplicate at the end of this process to give two daughter 
cells (Schmoller & Skotheim, 2015). These processes occur in a controlled manner. Some 
processes, like DNA replication, expression of some proteins, etc. are tightly controlled by 
cell cycle regulation at different phases. However, not much is known about how metabolism 
is coordinated with the cell cycle.  
Being an important player in main processes in the cell, when deregulated, metabolism also 
contributes to cancer progression and can even cause cancer transformation (King, Selak, & 
Gottlieb, 2006). These deregulated metabolic processes do not occur in normal proliferating 
cells (Fendt, 2017). After transformation, some enzymes or metabolites can gain a special 
importance for cancer cells, which can be called “addictions”. Targeting these metabolic 
addictions of cancer offers an attractive opportunity for killing cancer cells specifically. If 
these addictions happen in the vulnerable cell cycle phases between DNA synthesis and cell 
division, their targeting might be more effective.  
Metabolism is mostly measured in whole cell cultures or tissues, and not much is known 
about metabolism in subpopulations of culture, including cell cycle phases. In this regard 
there is a need to study metabolism across normal and cancer cell cycle; and identify 
metabolic activities upregulated in different cell cycle phases. Metabolites are high in 
number, very diverse in structure and chemical properties, making it technically challenging 
to measure cell metabolism. However, recent advances in LC-MS now offer possibilities to 
measure thousands of metabolites.  
A more detailed information about cancer metabolism, cell cycle and study methods is 
provided in the sections below. The background information is intended to provide a better 
understanding of why we want to understand the interplay between cancer metabolism and 
cell cycle, what is already known, and what is the best approach to measure these phenomena.  
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2 BIOLOGY 
2.1 Cellular metabolism and rewiring in cancer 
Metabolic pathways of central metabolism involve transformation and production of small 
metabolites such as amino acids, carbohydrates, fatty acids, keto acids, organic acids, and 
other organic compounds. The main functions of metabolic pathways in a cell are to 
synthesize macromolecules (proteins, lipids, carbohydrates) and maintain energy 
homeostasis. Based on the type of end products and energetics, reactions of central 
metabolism can be separated into two main groups: anabolic reactions that use nutrients and 
energy to synthesize complex macromolecules, like in gluconeogenesis, and catabolic 
reactions that involve degradation of energy-source molecules and release energy, like in 
glycolysis. Some other type of reactions have waste disposal functions and export metabolic 
products not needed by the cell, preventing their accumulation inside the cells (DeBerardinis 
& Thompson, 2012). Lactate and non-canonical nucleotides are some examples.  
The balance between anabolic and catabolic reactions is determined by the needs of cells for 
synthesizing or degrading macromolecules, releasing or using energy. When cells are 
stimulated by growth factors to grow and divide (Saltiel & Kahn, 2001), they upregulate 
nutrient uptake and anabolic reactions to meet the needs for macromolecules and synthesize 
DNA. Proliferating cells have upregulated pentose phosphate which synthesizes nucleotide 
precursors (ribose) and NADPH, increase glutamine uptake and fuel the TCA cycle, increase 
amino acid and fatty acid synthesis (Vander Heiden, Cantley, & Thompson, 2009). On the 
other hand quiescent cells, engage mostly in catabolic reactions to minimize macromolecule 
synthesis and maximize energy production in the absence of growth factor signals. While 
differentiated cells use the energetically efficient reactions of oxidative phosphorylation 
under aerobic conditions, proliferating cells have activated uptake of glucose and glycolysis 
in the presence or absence of oxygen (Brand & Hermfisse, 1997).  
Proliferating cancer cells are very similar to normal proliferating cells regarding metabolic 
requirements (DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008). However, cancer 
cells are cell sufficient for growth factors, undergo uncontrolled proliferation, and deregulate 
their metabolism to gain advantage for survival and growth. Even in the absence of growth 
factor signals, cancer cells are able to upregulate metabolism due to activation of oncogenes, 
inactivation of tumor suppressors or signals from the tumor microenvironment (Hsu & 
Sabatini, 2008). Oncogenic signaling directs cancer cells towards increased nutrient uptake 
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and anabolic pathways (Figure 1) while avoiding apoptosis (Plati, Bucur, & Khosravi-Far, 
2008). 
 
Figure 1. Upregulation of some metabolic pathways in proliferating cells.  
 
Deregulation of metabolic pathways in cancer cells often creates metabolic dependencies that 
make cancer cells different from normal proliferating cells and opens a window for effective 
targeting (Bi, Wu, Zhang, & Mischel, 2018). Activation of oncogenic signaling and 
deactivation of tumor suppressors which are responsible for cancer transformation, are the 
main cause for deregulation of cancer metabolism (Figure 2). Upregulation of oncogenes like 
PI3k, Akt, Her2/neu, myc is found to increase activity of glycolysis and anabolic pathways, 
and affect expression of metabolic enzymes toward favorable pathways (Tanner et al., 2018). 
Overexpression of Glucose Transporter 1 (GLUT1) is an example of deregulated metabolism 
that increases glucose uptake as directed by oncogenes mentioned above (Benjamin, Cravatt, 
& Nomura, 2012; Cantor & Sabatini, 2012). Tumor environment pH and low oxygen can 
also cause deregulations, but some features like excessive lactate production happen even 
before that stage (Vander Heiden et al., 2009).   
There are other scenarios of metabolic deregulation in cancer. One case is when mutated 
metabolic enzymes themselves cause cancer, acting as a tumor oncogene or suppressor. The 
TCA cycle enzymes, succinate dehydrogenase (SDH) and fumarate hydratase (FH), behave 
as tumor suppressors because they cause cancer when mutated (King et al., 2006). Other 
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cases include enzymes that have non-metabolic functions that provide advantages to cancer 
cells, like in the case of PKM2 which was found to translocate to nucleus and gain other roles 
that promote tumorigenesis (Ward & Thompson, 2012). Due to metabolic rewiring, cancer 
cells are known to develop dependencies on certain pathways which makes them auxotrophic 
for one or more amino acids, or activate other members of a metabolic enzyme family, which 
is different from normal cells (Cantor & Sabatini, 2012).   
 
Figure 2. Deregulation of metabolism in cancer. 
 
2.2 Cell cycle 
The cell cycle is a series of events where a cell grows, duplicates DNA and other components, 
until it divides into two daughter cells. The first records in the literature for the terms ‘cell 
cycle’ and ‘cell cycle phase’ are from 1951 by Howard and Pelc where they report a study of 
DNA synthesis in bean cells. The phase before DNA synthesis was called Gap 1, and the 
phase after DNA synthesis until division was called Gap 2 (Thoday, 1954). No other events 
except growth were known to happen during these phases. These cell cycle phases are now 
called G1 (Gap 1 or post-mitotic growth), S (Synthesis), G2 (Gap 2 or pre-mitotic growth) 
and M (Mitosis).  
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Physical changes during cell cycle 
To ensure that each daughter cell receives the same amount of material, the cell doubles all 
bulk properties and DNA until the end of division. Cell volume, dry mass and density 
(Mitchison, 2003), and even cell components like cytoplasmic organelles, plasma membrane, 
structural proteins and RNA (Morgan, 2007) continuously increase with cell cycle. 
Duplication of DNA is a major event that occurs once during the S phase of the cell cycle. 
Some proteins, including the cell cycle-regulating ones, have higher expression or activity, 
or change subcellular localization, in one cell cycle phase to ensure cell cycle progression.    
While there is no consensus on how to normalize measurement of proteins, metabolites etc., 
well-known bulk properties, like cell volume and total protein content that increase with cell 
cycle can be used. Due to increase in volume, an entity has to also increase in amount in order 
not to be diluted. Using cell numbers for normalization might not address this physical 
change of cells.  
Cell cycle regulation 
All cell cycle-related processes have to work perfectly and without any mistake to give two 
cells with identical genetic material and equally distributed bulk material. Therefore, the cell 
cycle is a tightly regulated process. The main mechanisms that drive cell cycle progression 
are controlled by oscillating expression or activity of regulatory proteins which ensure that 
events occur in the correct order. Activity of regulatory proteins is tightly controlled in time 
and localization. Cyclins that are expressed periodically during the cell cycle bind and 
activate the cyclin dependent kinases (Cdk), which in turn activate a cascade of events 
(Vermeulen,K.,Van Bockstaele,D.R.,Berneman, Vermeulen, Van Bockstaele, & Berneman, 
2003).  
Besides, normal cells have quality control checkpoints in every phase to monitor the main 
processes. Checkpoints ensure that events happen in a sequential order of events, and check 
that certain processes are completed and are error free before initiation of other events. The 
first point of control is the restriction point, which occurs 3-4 hours after mitosis (Ekholm, 
Zickert, Reed, & Zetterberg, 2001). The restriction point checks for availability of growth 
signals. This is a decision point whether to enter G0, the quiescent or resting state, until 
growth factors are available, or to commit to the cell cycle. Growth factors commonly initiate 
Ras signaling which activates a cascade of events, including Cyclin D which is a cell cycle 
regulating protein (Aktas, Cai, & Cooper, 1997). After the cell has decided to commit to the 
cell cycle, another checkpoint in late G1 (G1/S) checks the availability of amino acids and 
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energy status (Saqcena et al., 2013). This checkpoint is sensed by mTORC which is upstream 
of Akt and Cyclin E which is the second activated cyclin after Cyclin D. Once all checks 
prove successful, the cell proceeds through S phase and begins DNA synthesis. By the end 
of S phase, there is a checkpoint for DNA replication and DNA damage. DNA damage 
triggers another checkpoint active in G2-M phase (Vermeulen,K.,Van 
Bockstaele,D.R.,Berneman et al., 2003), responsible for sensing the DNA damages and 
stopping the cell cycle until damage is repaired. In G2 phase the cell has a last chance to check 
cell size, DNA replication and repair DNA damage (Chao et al., 2017). In mitosis, before 
cytokinesis, there is a last checkpoint which senses errors related to alignment of mitotic 
spindles with the chromosomes (Vermeulen,K.,Van Bockstaele,D.R.,Berneman et al., 2003). 
Possible misalignments lead to arrest in metaphase until repair.  
Cell cycle alterations in cancer 
When duplication of cell material, like DNA replication, is not done correctly and contains 
errors, but the cell fails to stop proliferation, these errors accumulate, and can result in further 
oncogenic mutations (Preston, Albertson, & Herr, 2010). Cancer cells often lose the tight 
control and regulatory mechanisms of cell cycle (Cantor & Sabatini, 2012), resulting in 
advantages like uncontrolled growth. Activation of oncogenes due to mutations provides 
continuous ligand-independent signal for activating pro-oncogenic processes and causing 
continuous uncontrolled proliferation. This happens when oncogenes like EGFR, Ras or Akt 
are mutated and inactivate the restriction point (Knauf et al., 2006). Some oncogenes cause 
overexpression of cyclins, Cdks and suppression of Cdk inhibitors in most cancer cells 
(Vermeulen,K.,Van Bockstaele,D.R.,Berneman et al., 2003). Having an inactivated G1  
restriction checkpoint (Diaz-Moralli, Tarrado-Castellarnau, Miranda, & Cascante, 2013), 
most cancer cells are forced to rely on the other checkpoints to control and repair DNA in 
case of mutations, incomplete replication, or other errors.  
Inactive checkpoints fail to promote fidelity and completion. When tumor suppressors, the 
cell cycle brakes, are mutated, the cell does not stop to repair the errors but continues 
uncontrolled proliferation. Activity of tumor suppressor p53 is frequently lost in cancers, 
providing an advantage to cancer cells by making them insensitive to stress conditions like 
accumulation of mutations or nutrient and oxygen deficiency. In normal cells, p53 mediates 
arrest at the G1 and G2-M checkpoints, but cancer cells that have lost p53 arrest at the spindle 
checkpoint when stress is applied in S phase and arrest in mitosis (Benada & Macurek, 2015). 
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A good understanding of these checkpoints and deregulations is crucial for targeting. 
Combining checkpoint inactivation due to oncogenic mutations with targeting of components 
of other checkpoints makes cancer cells more vulnerable during the committed phase. 
Normal cells are more resistant to these treatments since they have functional checkpoints. 
Accumulation of mutations and targeting of molecules related to S-G2 or spindle checkpoints 
results in defective cells in mitosis which eventually die (Gabrielli, Brooks, & Pavey, 2012). 
 
2.3 Oscillating metabolism 
Physical changes during cell growth suggest metabolic changes. In the literature, there is 
evidence of some metabolic events that oscillate across the cell cycle (Table 1). However, it 
still remains an open question to what extent metabolism is cell cycle-regulated in human 
cells. Most studies have been performed at the expression or protein level including several 
high throughput studies where they synchronize cells and perform microarray analysis (Bar-
Joseph et al., 2008; Cho et al., 2001; Stumpf, Moreno, Olshen, Taylor, & Ruggero, 2013; 
Whitfield et al., 2002). Other studies have reported enzyme activity and measurement of 
metabolite levels. Synchronization with double thymidine block (DTB), serum starvation 
and/or nocodazole are the most commonly used approaches for cell cycle phase separation 
(Section 3.1).  
DNA synthesis is the first cycling event known and the most studied. Enzymes used for 
nucleotide synthesis are also upregulated during S phase. Independent studies report that 
transcripts of Thymidine Kinase (TK) and Dihydrofolate reductase (DHFR) in fibroblasts 
(Denhardt, Edwards, & Parfett, 1986), and DHFR activity in Cho cells (Mariani, Slate, & 
Schimke, 1981) increase during S phase. A study in sorted lymphocytes reports that enzyme 
activity of TK, Thymidylate Synthase (TS) and DHFR reaches maximum in S-G2-M (Pelka-
Fleischer, Fleischer, Wilmanns, Sauer, & Schalhorn, 1989).  
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Table 1. Oscillating metabolic enzymes reported in the literature. 
 
Table 2. Oscillating metabolites reported in the literature. 
Polyamines are a group of positively charged metabolites that have been long studied for 
their interaction with DNA, stabilization, and potential roles in DNA protection and 
replication.  It is therefore not very surprising that polyamines and related enzymes are found 
to oscillate during the cell cycle. Putrescine, spermidine and spermine are the three types of 
polyamines, not containing the modified forms (acetyl- or carbamoyl- polyamines). All three 
contain ornithine minus a carbon dioxide in their backbone. Spermidine and spermine have 
three and six carbons respectively that derive from methionine via decarboxylated S-
adenosylmethionine (dcAdoMet). Independent studies in fibroblasts and Cho cells found that 
polyamine levels are lowest in G1 and increase gradually until they reach twice the amount 
in S phase. Ornithine decarboxylase (ODC) and Adenosylmethionine decarboxylase 
(AdoMetDC) activities which are part of the polyamine biosynthetic pathway, also increase 
towards the S phase while being lowest in G1 phase. (Bettuzzi et al., 1999; Fredlund, 
Johansson, Dahlberg, & Oredsson, 1995) 
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Figure 3. Polyamine synthesis from arginine and ornithine. Circles represent carbon atoms 
and squares represent nitrogen atoms.  
 
Also, glutamine utilization was found to be higher in the S-G2-M phase of HeLa cells 
synchronized with Nocodazole and DTB, but the mRNA of glutaminase enzyme GLS1, 
which converts glutamine to glutamate, is highly expressed in G1/S. Deprivation of glutamine 
or silencing of GLS1 caused cells to accumulate in G1 in nocodazole treated cells and in S 
phase for cells treated with DTB. (Colombo et al., 2011) 
As cells grow, so do cell membranes and metabolites that are required for membrane 
synthesis. Some studies report high levels of total fatty acids (Scaglia, Tyekucheva, Zadra, 
Photopoulos, & Loda, 2014) and cholesterol (Singh, Saxena, Srinivas, Pande, & 
Chattopadhyay, 2013) in S phase, while total phospholipid content increases throughout the 
cell cycle. The levels of lysophospholipids (metabolites in membrane phospholipid synthesis 
(Rivera & Chun, 2006)) increased steadily from G1 to S-G2-M (Scaglia et al., 2014). In 
another study, where HepG2 cells were synchronized by serum starvation and DTB, 
cholesterol synthesis increased in late G1 to mid-S phase (Sepp-Lorenzino, Rao, & Coleman, 
1991). HMG-Coa reductase (HMGR) activity which is the first enzyme in the mevalonate 
pathway that leads to cholesterol synthesis was highest in early-mid G1 phase.  
Depletion of metabolites causes cell cycle arrest 
Metabolic dependencies might create vulnerabilities for cancer cells. Some findings from 
recent studies suggest that depriving cancer cells of certain metabolites can cause cell cycle 
arrest and cell death (Isono, Chano, Kitamura, & Yuasa, 2014; Patel et al., 2016; Scott, Lamb, 
Smith, & Wheatley, 2000). Other studies, including high throughput studies where cells were 
treated with siRNAs to silence different metabolic enzymes, report cell cycle arrest or 
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proliferation problems (Björklund et al., 2006; Grant et al., 2013; Kittler et al., 2007; 
Mukherji et al., 2006).   
Some cancers develop amino acid dependencies, and when deprived of amino acids undergo 
cell cycle arrest and cell death. Asparagine depletion arrested Cho cells in G0/G1 phase 
(Fomina-Yadlin et al., 2014). Treatment with arginine deiminase (ADI), that deprives cells 
of arginine, was found to arrest cultured lymphatic leukemia cell line in G1 and/or S phase 
bringing them to apoptosis later (Colombo et al., 2011; Gong, Zölzer, von Recklinghausen, 
Havers, & Schweigerer, 2000; Patil, Bhaumik, Babykutty, Banerjee, & Fukumura, 2016). 
Leucine deprivation was seen to induce arrest at G1 phase of 3T3 and Cho cells (Wynford-
Thomas, LaMontagne, Marin, & Prescott, 1985). Blocking FASN by enzyme inhibitors 
induces cell cycle arrest at S and/or G2-M (Veigel et al., 2015).  
Polyamine analogues that cannot be metabolized by cells were introduced to MCF7 and other 
breast cancer cell lines, and an accumulation of cells in G1 was observed (Fredlund et al., 
1995; Holst, Frydman, Marton, & Oredsson, 2006; Johansson, Oredsson, & Alm, 2008). Cho 
cells were depleted of polyamines by using an inhibitor that blocks ODC, which caused a 
delay in S phase. Addition of putrescine restored the phenotype, confirming that polyamines 
are required for cell cycle progression and are sensed by a checkpoint close to S phase 
(Harada & Morris, 1981). Other enzymes in the arginine catabolism pathway, upstream of 
the polyamine biosynthesis pathway, perturb growth and cell cycle regulation when inhibited.  
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3 METHODOLOGY 
In this section, I describe available methods that are used to measure metabolites and separate 
cell cycle phases. Some of the methods described below were used in the research work 
presented in Thesis section.   
3.1 Cell cycle separation 
Obtaining pure fractions of cell cycle phases is crucial for generating reliable data when 
studying cell cycle related processes. Cell sorting based on fluorescent markers and 
synchronization with chemicals that block cell cycle progression are the two main approaches 
that have been used for separation of cells into cell cycle phases.  
3.1.1 Fluorescence Activated Cell Sorting 
FACS (Fluorescence Activated Cell Sorting) is by far the most versatile and widely used tool 
for separating cell populations. Individual cells are passed through a capillary and separated 
into tubes based on fluorescent markers detected by laser. A fluorescent molecule is either 
conjugated to antibodies binding to cycling proteins in the cell, or a gene coding a fluorescent 
protein is co-expressed with a cell cycle related protein in engineered cell lines (Howard M. 
Shapiro, 2005). Several examples of engineered cell lines are reported in the literature: PCNA 
(Kisielewska, Lu, & Whitaker, 2005), helicase B,  DNA ligase (Easwaran, Leonhardt, & 
Cardoso, 2005) have been used as S phase markers; cyclin B1 as a G2-M phase marker 
(Schnerch, Follo, Felthaus, Engelhardt, & Wäsch, 2013); and ubiquitin ligase based geminin 
(FUCCI) as a marker for S-G2-M (Sakaue-Sawano et al., 2008) are some reported examples.  
Cells can be separated based on their DNA content, since G1 cells have one copy of DNA 
and S-G2-M cells have two copies of DNA. Some small molecules bind or intercalate the 
DNA, providing a reading for DNA content. Hoechst-34580 is permeable to live cells, 
allowing for live cell staining and analysis, while other dyes like DAPI and PI are used in 
fixed cells.  
3.1.2 Synchronization 
Synchronization methods are based on cell cycle arrest due to introduction of chemicals that 
interfere with cell cycle processes of DNA replication, microtubule formation and cholesterol 
synthesis (Banfalvi, 2011a; Ma & Poon, 2011). This approach was used in early years of cell 
cycle research when more advanced separating tools were not developed, and it is still widely 
used in cell cycle studies. In the double thymidine block technique (DTB), applying two 
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treatment intervals with thymidine halts DNA replication due to an imbalance of nucleotides, 
and blocks cells in S phase (Engstrom & Kmiec, 2008). Nocodazole blocks microtubule 
formation which forces cells to stop in M phase, while lovastatin which blocks the 
mevalonate pathway and downstream cholesterol synthesis, and stops cells in G1 phase 
(Keyomarsi, 1996). Serum deprivation is another approach used to study cells in G1 phase, 
but it is thought to bring cells to G0 (quiescent, non-proliferating state) due to lack of growth 
factors (Cooper, 1998). Physical separation of cells in different phases by centrifugal 
elutriation based on cell size (Banfalvi, 2011b; Diamond, 1991) and mitotic shake-off 
(Terasima & Tolmach, 1963) are other approaches for synchronizing cells. Synchronization 
is the method of choice, especially in high throughput studies, where it is practically difficult 
to obtain hundreds of sorted populations. 
After synchronization, cells are released from the block and allowed to grow in normal 
medium for different periods of time and progress in cell cycle, to allow collection of cells 
in different phases. To assess the cell cycle progression after synchronization, methods like 
cell counting, incorporation of nucleoside analogues, DNA stains, cell cycle reporters, etc. 
are used (Henderson, Bortone, Lim, & Zambon, 2013). 
3.1.3 Comparing methods 
Synchronization does not require any special equipment, it is not complicated and large 
amount of cells can be obtained with synchronization. However, the procedure has to be 
optimized for each cell line and phase of synchronization, because some cells might not 
respond to standard synchronization procedures. Different cell lines require different 
concentrations and incubation times. While allowing dissection of cell cycle phases in shorter 
intervals due to release at different time points, cells start to lose synchrony after release. The 
block is not perfect, so that a high percentage of cells are synchronized in one phase while a 
small percentage of cells is in other phases. Moreover, treating cells with chemicals to block 
some processes in the cell can be “invasive”, in that their action is based on halting metabolic 
processes to force arrest in a particular phase. This can nonspecifically distort physiology and 
metabolism, sometimes making the downstream experiments more difficult to interpret.   
Cell sorting, on the other hand, provides a cleaner separation of the cell cycle phases, does 
not disrupt metabolic reactions by drugs, and can be applied to any cell type. The 
disadvantage of sorting is the long sample processing time, need for specialized equipment 
and requirement for good fluorescent staining.  
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3.2 Metabolite measurements 
Metabolite measurement are important when comparing different conditions like cell 
transformation and drug treatment. In early biochemistry studies, enzymatic assays were used 
to measure levels of metabolites. As technology advanced, methods like high-performance 
liquid chromatography (HPLC), later nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) were used to separate and measure metabolites in samples. The popularity 
of these methods has changed with time, and nowadays various MS methods are used more 
widely, due to development of methods and technology (Figure 4). Today these methods 
continue to be used and sometimes in combination in order to increase coverage of measured 
metabolites. The wide range of metabolites and the variety of their chemical structure is a 
challenge for using one method. Often, methods that measure a specific class of metabolites 
with certain properties (e.g. polar metabolites) are developed.  
 
Figure 4. Publications that include one of the terms (MS, NMR, MS&NMR, HPLC) in 
title/abstract. Numbers are reported per year. Data are obtained from Pubmed.  
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3.2.1 Mass Spectrometry (MS) 
Mass spectrometry (MS) and NMR are the main techniques in metabolomics, the 
measurement of metabolites. MS is advantageous because of the higher resolution and 
sensitivity, which makes it suitable to analyze low abundance molecules or small samples. 
MS is often coupled to GC (gas chromatography) or LC (liquid chromatography). LC is based 
on liquid phase separation of compounds and allows separation of most metabolites, whether 
they are polar, non-polar, acidic or basic; while GC works best for separation of non-volatile 
or highly polar compounds (Ramautar & de Jong, 2014),(Milne, Mathews, Myers, Ivanova, 
& Brown, 2013). Using either of these methods, metabolites can be analyzed for their relative 
abundance. Quantification of metabolites in unlabeled samples is done by calculating the area 
under the LC peak (Figure 5). Peaks areas can be considered as the relative abundance of the 
metabolite, although it might be difficult to compare between very different types of samples 
(Figure 5).  
 
Figure 5. LCMS sample analysis and data processing.  
 
3.2.2 Nuclear Magnetic Resonance (NMR) 
NMR is based on the principle that the nucleus of some atoms can behave like a magnet, due 
to having a charge and spin. These nuclei, like 1H, 13C, 19F, 31P, 2H, that have a charge and 
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spin are called “NMR active”, while others, like 12C and 16O are “NMR inactive” meaning 
that they do not produce NMR signal (Brevard & Granger, 1982). Based on these properties, 
in NMR, a magnetic field is applied to nuclei and the amount of energy to put nuclei in 
resonance in measured. The produced NMR spectrum is composed of signals reflecting the 
required energy to bring the NMR active nuclei into resonance. It is possible to separate 
molecules from each other based on the fact that different nuclei require different amount of 
energy depending on position in a molecule (surrounding atoms/shielding effect – affected 
by electronegativity of surrounding atoms). (Komoroski, Pappas, & Hough, 1991; Mlynárik, 
2017)  
NMR can be used to analyze both liquid and solid samples, including tissues, sample can be 
reused and stored for further analysis. Obtained data provides information about chemical 
structure, because produced signals reflect the chemical bonds between atoms (Emwas, 
2015). NMR is fast and produces very reproducible data, but also requires high amount of 
sample and specialized staff. The instrument takes a lot of space and is expensive to operate. 
3.2.3 Other methods 
Other methods used for metabolite measurement and quantification are High Performance 
Liquid Chromatography HPLC and enzymatic assays.  
HPLC is an advanced analytical technique compared to liquid chromatography developed in 
the mid-1960s. The separated sample is in liquid form, and it is quite fast. With HPLC it is 
possible to separate chemicals with high selectivity by optimizing the dissolving solution, 
and is widely used in pharmaceutical research to separate chemical products. (Snyder, 2000) 
Enzymatic assays for metabolite measurements are nowadays mostly used as commercially 
available kits. These assays are based on a chain of conversion reactions. An enzyme converts 
the substrate (metabolite) into a product, which is coupled to oxidation or reduction of 
pyridine nucleotides  (Newsholme & Taylor, 1968), or to a chain of reactions that involves 
conversion of a marker molecule. In the case of pyridine nucleotides, the light absorption 
changes due to oxidation or reduction and the difference in light absorption is measured. A 
similar principle is valid for marker molecules. In enzymatic kits that are widely used 
nowadays, Amplex red is converted resofurin, in a reaction that is mediated by HRP. This 
reaction is coupled to conversion of H2O2 to water. H2O2 is usually the byproduct in a reaction 
connected to the metabolite of interest (Summers, Zhao, Ganini, & Mason, 2013). Enzymatic 
assays can be highly specific, but the marker molecules are usually very sensitive to light and 
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produce high background signal. The kits are quite expensive, and measure only one 
metabolite at a time, but can be useful for quick measurements. When ATP/ADP, ATP/AMP 
(measures of energy status) and NADPH/NADP+ measurements were used to assess the 
methods above, MS measurements were found more accurate (Lu et al., 2017).  
3.3 Assessing enzyme activity - isotope tracing 
To characterize and compare cancer and normal cells, it is important to assess enzyme 
activities. Enzyme activity can be measured directly with enzymatic assays, which are a 
precise measurement of activity. However, these enzymatic assays measure activities in 
lysates and not in live cells. Another disadvantage is that it is very difficult to perform 
enzymatic assays for hundreds of metabolic enzymes in a high throughput study. Metabolite 
abundance, which are calculated by integrating peak areas, might be used to infer enzymatic 
activity, but it is difficult to give conclusions because one metabolite can be synthesized from 
different enzymes. Besides, metabolites abundance is a result of both synthesis and 
consumption of a metabolite. A better approach, which we adopted in this thesis, is the 
isotope tracing approach, where we infer enzyme activities from label incorporation into 
metabolites in living cells.  
In isotope tracing, cells are cultured in labeled nutrients which are used for synthesis of other 
intracellular metabolites that acquire label. Isotope tracing can be performed with stable 
isotopes or radioisotopes. Radioisotopes were widely used in the past, but are difficult to 
handle. Heavy isotopes, on the other hand, are more practical because they are not toxic and 
can be used for tracing in animals and even patients.  
Depending on the question, isotope tracing can be performed for a long time (steady state) or 
short time (pulse labeling). Choosing one approach or the other affects data interpretation. 
Pulse labeling experiments are performed to study timed processes like cell cycle phases or 
fast reactions. In pulse labeling experiments, isotope labeling can be analyzed by comparing 
peak areas of the relevant heavy isotopomer. In the case of steady state labeling, it is possible 
to calculate mass isotope distribution (MIDs), which sum up to one. In both cases it is 
possible to calculate the enrichment of the heavy isotope atoms for each metabolite, by using 
the formula: ∑ 𝑥𝑥 ∗ 𝑀𝑀𝑀𝑀𝑥𝑥/𝑛𝑛𝑛𝑛𝑥𝑥=0   where, n is the total number of carbons in the metabolite and 
MIx is the MI fraction of x. A mass isotopomer (MI) is a metabolite with higher mass due to 
incorporation of heavy isotope (Hellerstein & Neese, 1999).  The MI fraction is defined as a 
fraction of abundance (concentration, pool size), calculated by dividing peak area by the total 
peak areas for all MIs of a metabolite. The set of all MI fractions is often termed mass 
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isotopomer distribution (MID) (Figure 6). Both peak areas and MIDs provide valuable and 
different information.  
The isotope distribution of any given metabolite reflects the cell’s metabolic activity before 
extraction of metabolites. Also, the MID is calculated by rescaling all MIs 0-1, so each MI 
fraction is considered as a ratio. This makes the data more robust (less affected by 
experimental condition), and gives information on the metabolic pathways (Bennett, Yuan, 
Kimball, & Rabinowitz, 2008). The challenge here is that it is an indirect measurement of 
the enzyme activity. Sometimes one metabolite is synthesized by more than one enzyme. 
This can be difficult to evaluate.  
 
Figure 6. Illustration of peak areas and mass isotopomers. a) Chemical structures of glucose 
and lactate. b) Mass Isotopomer (MI) distribution of lactate when cells are cultured in 
medium containing 60% U-13C-glucose. Each circle represents one carbon in the molecule. 
M+1 is the mass isotopomer containing 1 13C in the structure. c) Peak areas of lactate MI 
when cultured in 60% U-13C-glucose d) Lactate MIDs.  
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THESIS 
In this thesis, I presented a study of metabolism in G1 and S-G2-M cell cycle phases to identify 
metabolic enzymes that are important for cancer cell proliferation. There is evidence in the 
literature that some metabolic events are cycling, and in this thesis I aim to answer related 
questions which are not addressed in the literature. What does the big picture of metabolism 
across cell cycle look like? What fraction of metabolites is oscillating? While many proteins 
(~15%) are oscillating at the mRNA level, is this valid for the enzyme activities as well? Are 
certain metabolites required for cell cycle progression? Our hypothesis is that some 
metabolites might be important for cell cycle progression and we want to identify those. To 
test this hypothesis, I investigated metabolites that are more abundant in the S-G2-M phases 
and affect cell cycle progression (Figure 7a). I did not follow housekeeping metabolites 
required and synthesized throughout cell cycle (Figure 7b). The work presented here 
includes method development, metabolomics, data analysis and follow-up experiments that 
resulted in 4 papers, which are discussed in the following sections. 
  
Figure 7. Models illustrating situation where metabolites affect cell cycle progression. a) A 
cell cycle regulator protein (C) activates E at one of the cell cycle phases, and higher M 
abundance in that phase is required for cell cycle progression. b) Enzyme (E) activity and 
metabolite (M) levels are constant across cell cycle, but presence of metabolite is sensed at a 
particular cell cycle checkpoint and is important for cell cycle progression. 
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1 AIMS 
The overarching aim in this thesis is to identify metabolic enzymes that are important for 
proliferation of cancer cells, and make cancer cells vulnerable to targeting. To achieve this, 
we separated the project into sub-studies and set aims for each.  
 
Aim 1.  Develop a method for studying metabolomics of subpopulations 
- Find and optimize a method for separating cells into subpopulations. 
- Develop a metabolite extraction method that will minimize metabolic disturbances. 
- Try different approaches for metabolic measurements, including relative metabolite 
abundance and isotope tracing.  
 
Aim 2.  Perform metabolomics of cells in G1 and S-G2-M cell cycle phases 
- Optimize a cell cycle marker to separate live cells into G1 and S-G2-M cell cycle 
phases and minimize disturbances to cell metabolism. 
- Optimize pulse labeling experiments with isotope tracing to study metabolic activities 
in G1 and S-G2-M phases. 
- Perform metabolic experiments in cell cycle sorted normal and cancer cell lines.  
 
Aim 3.  Integrate available cell cycle data with metabolomics data generated in this project 
to identify interesting enzymes that show high activity and expression in the S-G2-M phases. 
- Make use of available datasets on protein expression and proteomics in different cell 
cycle phases, as well RNAi screenings.   
 
Aim 4. Perform follow-up experiments to verify the role of identified enzymes for cell   
proliferation, and compare enzyme activity in normal and cancer cells.  
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2 RESEARCH DESIGN 
 In order to address the aims in this thesis, I implemented a strategy where I combined 
Method development (aim 1), hypothesis-generating (aim 2, 3 and 4) and hypothesis 
testing (aim 5) approaches, as illustrated in Figure 8. A method was developed to study 
metabolic activities in sorted subpopulations. Application of this method to study 
metabolomics of G1 and S-G2-M phase cells generated hundreds of metabolites captured 
with an LC-MS method, of which a fraction with higher abundance in one phase. 
Mapping these results from metabolomics against other datasets on cycling expression 
and hits from previously published RNAi screening, generated a shortlist of “hit” 
enzymes with potential effect in cell proliferation. I then and performed follow-up 
experiments to validate these hit enzymes.   
 
Figure 8. Research design including method development, hypothesis generating and testing. 
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3 RESULTS AND DISCUSSION 
In this section I will summarize the findings from Papers I-IV, and discuss results and 
challenges. 
3.1 Method development 
Many biological samples, including cells in different phases of the cell cycle, are a mix of 
subpopulations. We developed a method that, in principle, enables metabolomics studies in 
any subpopulation of cells for which there are available markers. As described in Paper I, we 
chose the approach of combining fluorescence activated cell sorting (FACS) and liquid 
chromatography - mass spectrometry (LC-MS).  
Measurements of cell metabolite content are prone to artifacts due to experimental procedures 
following cell detachment from culture dish. Therefore, we sought a solution that would 
allow to obtain subpopulations using FACS sorting while minimizing the metabolic 
distortion. We proposed a direct extraction method to shorten the sample processing time 
from sorting to metabolite extraction, by sorting cells into tubes containing the extracting 
solution, 100% methanol. When these samples were analyzed on LC-MS, metabolic signal 
seemed to be distorted and suppressed. When cells are sorted, they are surrounded by sorting 
solution which has a high salt content, similar to Hank's Balanced Salt Solution (HBSS). 
When cells are processed for MS analysis, they are evaporated and concentrated under 
vacuum using a Speed-Vac. This essential step, increases the concentration of salts several 
folds. Although the direct extraction provided an immediate extraction of metabolites, salt 
concentration was a limitation, and this method was abandoned. 
We instead chose a method where we sorted cells into tubes, removed sorting solution by 
centrifuging and extracted metabolites from pellets. To minimize any metabolite leakage 
from cells due to osmosis and avoid cell lysis upon collection, cells were sorted into tubes 
containing HBSS and 5% dialyzed Fetal Bovine Serum (FBS). Cell sorting rate 
(1000events/sec) and nozzle size (100µm) were also optimized to minimize metabolic 
disruption during sorting.  
To assess the method and for future reference (as used in Paper II, III and IV), we aimed to 
measure both metabolite abundance and metabolic activities and compare their integrity. We 
cultured cells both in unlabeled medium (all nutrients 12C), and in labeled medium containing 
labeled U-13C-glucose and U-13C,15N-glutamine. Glucose and glutamine feed into a large part 
of cellular metabolism (Palm & Thompson, 2017), giving the opportunity to evaluate several 
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metabolites. We extracted cells from FACS-sorted fractions, directly from culture dish, and 
from a pellet of cells, which is an intermediate step between the first two. We found that peak 
areas reflecting the relative metabolite abundance were quite different. One possible cause is 
metabolite leakage during sorting. However, nucleotide peaks had a higher signal in sorted 
samples, suggesting that the differences we observe could be due to the difference in 
chemical matrix. It also has to be considered that comparisons in future studies will be 
between sorted fractions of the same samples which should be affected in the same way by 
sorting procedure.  
On the other hand, data obtained from isotope tracing should be more robust and less affected 
by sorting procedures. Isotopic labeling is a readout of the metabolic activities when cells are 
in culture, and should reflect what happened in culture before sorting. Label incorporation to 
metabolite was evaluated by calculating mass isotopomer distribution (MID), which means 
fraction of MI abundances (See Section 3.32.3). Since there should not be biased selection 
of MIs, even in the case of metabolite leakage, MIDs should be less affected by sorting. 
However, we found that some glycolysis metabolites like lactate, had different MIDs in 
sorted cells as compared to cells directly extracted from the dish. One reason could be the 
presence of FBS in sorting solution. Glycolysis is a fast reaction that happens within minutes, 
and MID differences could be due to unlabeled glucose in FBS. Due to these difficulties, 
control experiments are recommended to be performed when starting experiments with a new 
cell type. Such comparisons between extractions in culture dish and sorted cells were 
performed for studies reported in Paper I and II.  
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3.2 Mapping metabolism across the cell cycle  
We used the method developed in Paper I to study metabolism in different cell cycle phases 
as presented in Paper II and III, which allowed mapping of metabolite abundances and 
metabolic activities in G1 and S-G2-M phases. To identify metabolic enzymes active in cell 
cycle phases and that may have a role in cell proliferation, we combined data from our 
metabolomics study with cell cycle mRNA expression data and cell cycle siRNA screening 
from published datasets, as illustrated in Figure 9.  
 
Figure 9. Integration of data from mass spectrometry, RNAi screening and microarray to 
identify cycling metabolic events from different levels.  
 
3.2.1 Charting metabolism in G1 and S-G2-M phases  
The key to sorting cell subpopulations is to have a specific marker. Fortunately, there are 
many cell cycle markers developed, including DNA staining and cyclin probes. Initially we 
sorted cells based on an internal fluorescent (Fucci) probe, Geminin, which fluoresces in S-
G2-M phases (Paper I). Cell lines with internal probes are quite easy to handle, but the 
experiment is limited to engineered cell lines, which require additional efforts to produce. 
We sought alternative methods for separating cells into cell cycle phases by staining DNA in 
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live cells. DNA is an established marker for cell cycle that makes possible separation into G1 
and S-G2-M phases, which we are interested in.  At the time, a new commercial dye, sir-DNA 
(Lukinavičius et al., 2015), promised live DNA staining without causing toxicity to cells 
when cultured for 24 hours. However, in our hands, micromolar concentration of sir-DNA 
and verapamil, which blocks Ca++ channels to avoid dye efflux, did not produce good 
intensity for sorting experiment. Next we explored live cell staining with Hoechst-34580, 
which can be detected with a 405nm laser which is commonly found in sorting devices 
(Darzynkiewicz, Juan, & Srour, 2004; H M Shapiro & Perlmutter, 2001). Different Hoechst 
staining concentrations and staining protocols were first tested in cell pellets, then optimized 
for staining of cells in the culture dish, minimizing the processing time before sorting and 
possible metabolite leakage that might happen when cells are detached in solution.  
For these experiments we selected the tumor-derived cell lines HeLa (ovarian cancer) and 
MDA MB 231 (breast cancer); a telomerase-immortalized human mammary epithelial cell 
line (HMEC-Tert) and a derived cell line that was transformed with the SV40 early region 
proteins followed by a mutant Ras protein (HMEC-RAS, tumorigenic in vivo) (Elenbaas et 
al., 2001). Cells were cultured for 48 hours, stained with Hoechst and sorted into G1 and S-
G2-M, extracted, and then analyzed on LC-MS. All cell lines were cultured both in unlabeled 
medium and in medium containing 13C labeled amino acids and glucose (“fully” labeled 
medium). We observed a larger number of peaks and higher peak intensity in the HeLa cells 
dataset. Therefore this dataset was used for peak annotation and initial data analysis.  Data 
obtained from other cells was used to compare interesting finding from the HeLa cells 
datasets.  
Using an in-house developed peak detection software, we obtained 3426 peaks after 
removing unspecific peaks from blanks, and annotated 921 peaks by mapping the m/z in our 
list against the HMDB database. Metabolite abundances were calculated by integrating area 
of metabolite peaks as reported in Paper II. Considering the increase in cell volume across 
the cell cycle, a reasonable normalization factor is required to evaluate metabolite abundance 
in G1 and S-G2-M phases. One option is to normalize peak areas to cell size, measured 
indirectly by forward scatter in FACS instrument. The calculated ratio S-G2-M / G1 was 1.16. 
Thinking that a cell doubles in size over the cell cycle, a ratio of 1.16 might sound too low. 
However, here we take the average of cells in S-G2-M and G1, respectively. In fact the 
theoretical biomass ratio between the G1 and S-G2-M fractions was calculated as 1.39. On 
the other hand, the forward scatter calculations might have not been exactly the same as the 
sorted cells, because FACS instrument allows export of raw data without gating details 
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applied for during sorting. For this reason, we argued that the sum of peak areas for the 921 
metabolites (T921) cound be a good measure. It was reassuring to find that T921 was strongly 
correlated with the number of cells (a measure for biomass) analyzed in MS. The calculated 
T921 between S-G2-M and G1 was 1.19.  
Using this normalization factor, we normalized all peak areas and found that 82% of 
metabolites did not change between phases. The rest was at least two fold more abundant in 
one of the phases. Most metabolites, including most proteinogenic amino acids and 
phosphatidylcholines that take part in macromolecular and membrane synthesis (Hosios et 
al., 2016), follow a similar trend as cell size, volume and protein content, showing a 
continuous need for metabolites as cells proceed to division. The fraction of cycling 
metabolites was 15%, and corresponded to 15-18% of mRNA transcripts that are known to 
be cyclic in HeLa cells (Grant et al., 2013).  
To measure metabolic activities in G1 and S-G2-M phase cells, we applied pulse labeling with 
fully labeled medium as described in Paper III. Pulse labeling is suitable for cell cycle studies, 
because cell cycle phases occur during short windows of time, ~7 hours. In order to avoid 
labeling of metabolites in one phase and sorting in another, we selected an isotope tracing 
window of 3 hours.  
DNA synthesis was used as a positive control in our experiments. Both abundance of NTPs 
and activity of related enzymes was higher in S-G2-M phases. Phosphorylated pentose sugars 
were more labeled and in higher abundance in G1 phase. Other cycling metabolites are 
discussed in Paper II and III. These experiments represent a large-scale investigation of 
metabolite abundances and metabolic activities in G1 and S-G2-M phases, and curated a large 
dataset of 3426 peaks, one third of which is currently annotated. Therefore, there is great 
opportunity for discovering other metabolites that are hitherto not known to be cycling.  
3.2.2 Data integration 
We selected and retrieved several datasets of mRNA gene expression data across the cell 
cycle, and RNAi screens for cell cycle phenotypes. We extracted data for metabolic enzymes 
and prepared a shortlist of metabolic enzymes that are cycling and/or cause a cell cycle 
phenotype when knocked down. This list was mapped against our metabolomics dataset, to 
identify those pathways that were more active in one cell cycle phase in at least two types of 
measurement.  Arginase 2 (ARG2), that mediates ornithine synthesis from arginine, and 
 34 
Choline dehydrogenase (CHDH), that catabolizes choline to synthesize betaine aldehyde, 
were in the shortlist, and are further describe below.  
3.2.3 Arginase 2 is important for proliferation in S-G2-M phases 
While most amino acids acquired similar 13C labeling in both sorted fractions, arginine and 
lysine were more labeled in S-G2-M phases. Similarly, ornithine, but not other downstream 
metabolites of arginine were more labeled in S-G2-M phases. Ornithine is synthesized from 
arginine through the mitochondrial arginase (ARG2), and is the precursor of polyamines that 
are required for DNA maintenance and cell proliferation. Interestingly, ornithine acquired 
more label in S-G2-M phases of HeLa and HMEC Ras, but did not acquire any label in HMEC 
Tert immortalized cells during 3 hours pulse labeling with fully labeled medium. We 
proposed that HMEC Tert might be using another, slower reaction for ornithine synthesis. 
Ornithine transferase (OAT) is known to mediate an alternative reaction of ornithine 
synthesis from glutamine. To assess the sources of ornithine, we performed U-13C-arginine 
and U-13C-glutamine steady-state tracing in cancer and normal cells. Interestingly, cancer 
cells synthesized ornithine only from arginine, but normal cells used both arginine and 
glutamine as sources for ornithine. These results strengthened the hypothesis that ARG2 
could have a role in cancer cell proliferation. To verify this, we silenced ARG2 with 7 
independent hairpins from 2 different vendors, and 4 of them that showed good 
downregulation, reduced cancer cell proliferation by half.  It is certainly important to 
investigate how normal cells respond to such treatments. We tried transient knockdown of 
HMEC Tert cells with special reagents for this cell type, but the knockdown was not 
successful. We also tried 3 different arginase inhibitors, which were used at high micro molar 
range. However, a recent study found that such inhibitors decrease cell proliferation 
independently of arginase enzyme (Ng et al., 2018). Indeed we found a decrease in cell 
number in both normal and cancer cells.  
To assess the relevance of these findings to human tumors, we investigated ARG2 expression 
in patient samples. We searched for most available tumor normal datasets in GEO (Edgar, 
2002) and Oncomine (Rhodes et al., 2004), but no overall significant difference was found 
between normal tissues and cancers. However, when we looked closer tumor subtypes, we 
found a correlation of ARG2 overexpression with estrogen receptor (ER) negative and basal 
(based on PAM50 classification) breast cancers. In addition ARG2 overexpression also 
correlated with bad survival in ER negative and basal tumor subtypes. Thus, ARG2 may be 
relevant in these particular tumor types.  
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3.3 Survey of choline metabolism 
CHDH, the enzyme that converts choline to betaine aldehyde, was one of the “hit” enzymes 
in the data integration short list (See section 3.2.2 Data integration). Motivated by the fact 
that a survey of choline products in proliferating normal and cancer cells was missing, we 
performed a detailed characterization of choline in several cell lines and reported the data in 
Paper IV. We cultured HMEC Tert, HMEC SV40 (transformed with the SV40 early region 
proteins, (Elenbaas et al., 2001)), HMEC Ras, MCF7 (breast carcinoma), HeLa and HCT116 
(colon carcinoma) cells in medium that contained 50% 13C3-choline, labeled in 3 methyl 
groups.  
Interestingly, betaine was labeled in cells with cancer origin but not in normal cells, 
suggesting absence of CHDH activity in HMEC cells, which was confirmed by western blot 
analysis of CHDH expression. Knockdown of CHDH resulted in good downregulation of the 
enzyme and also decreased betaine labeling in MS data. CHDH knockdown did not affect 
cell proliferation in our culture conditions (in normoxia). However, 2 out of 4 siRNAs caused 
an increase in G2-M phases when CHDH was knocked down.  
Betaine was likely not used for methylation or synthesis of other products, since sarcosine, 
methionine and S-Adenosyl methionine (SAM) were not labeled from 13C3-choline.  The 
question is: what is the role of betaine in cancer cells? Some previous studies suggest that 
betaine can act as an osmolyte. To test this, we measured betaine concentration in cell extracts 
and spent medium. Betaine concentration was in the low micro molar range both in cell 
extracts and spent media of cancer cells, indicating that betaine cannot be an osmolyte in 
these cells. It is possible that betaine synthesis was required for proliferation of tumor cells 
in vivo, but has lost this function since we are growing cells in dish. Follow-up experiments 
in tumor tissues will help to address this.  
Finally, choline tracing produced thousands of peaks detected by LC-MS. From untargeted 
analysis we obtained 4908 peaks in positive and negative ion modes after subtracting 
unspecific peaks in blanks. 122 peaks were labeled from choline, of which 96 peaks were 
labeled in 3 carbons, suggesting that the head group of choline is donated. Metabolites labeled 
in 3 carbons include phosphocholine, CDP-choline and glycerol-phosphocholine from 
phospholipid metabolism, showing active phospholipid metabolism in all selected cells. 26 
peaks were labeled either in 1 or 2 carbons. Since these cells do not use choline for 
methylation, the 1 or 2 carbon labeled peaks are likely catabolites of choline. While most of 
the 26 peaks are unknown, we mapped m/z with HMDB database (Wishart et al., 2013) and 
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found two peaks corresponding to m/z of methylethanolamine phosphate (P-MME) and 
dimethylethanolamine phosphate (P-DME) labeled in one and two carbons, respectively. 
These two metabolites are known as part of PC synthesis from PE methylation from SAM, 
or as part of Phosphatidyl methylethanolamine (Ptd-MME) and Phosphatidyl 
methylethanolamine (Ptd-DME) synthesis. However these reactions are not described in 
human cells before, and may be interesting for follow up studies.  
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4 CONCLUSIONS 
4.1 Summary 
In this thesis I presented a comprehensive study of metabolism in normal and cancer cells 
sorted into G1 and S-G2-M phases of the cell cycle. This was achieved through a method we 
developed by combining cell sorting, isotope tracing and high resolution liquid 
chromatography mass spectrometry (HRLC-MS), which permitted measuring and identifying 
hundreds of metabolite peaks. Isotope tracing was used to measure metabolic activities in 
sorted cell cycle phases. Culturing of cells in medium with 13C nutrients in a pulse labeling 
experiment ensured good coverage of most metabolites synthesized internally by the cells. 
Most metabolic activities and metabolite abundances did not oscillate, suggesting the need for 
metabolites to support cell growth and building of biomass throughout the cell cycle. A few 
hundred metabolites acquired more label and/or had higher abundance in G1 or S-G2-M phases. 
To select hit enzyme candidates for follow up validation experiments, we integrated 
metabolomics data from this study, cyclic gene expression and siRNA screening. We chose to 
follow up on arginase 2 (ARG2) and choline dehydrogenase (CHDH) enzymes. A large part 
of cyclic peaks that were not annotated or were annotated but not known before to be cyclic, 
remain to be explored in further studies. 
Ornithine was one of the metabolites that acquired more label in S-G2-M phases of cancer cells, 
but was not labeled in normal cells within 3 hours pulse labeling experiment. Other steady state 
tracing experiments with single labeled amino acids verified that arginine, via ARG2, was 
responsible for higher ornithine labeling in cancer cells in pulse labeling experiment. Cancer 
cells used only arginine as a source for ornithine synthesis, while non-cancer cells used both 
arginine and glutamine via ornithine aminotransferase (OAT). ARG2 was later found to reduce 
the cell number by half when ARG2 was silenced for a short period of around 24 hours. The 
OAT enzyme, on the other hand, did not compensate for ornithine synthesis during ARG2 
knockdown. In a large-scale survey of patient tissue samples, we found that ARG2 
overexpression correlated with ER negative and basal breast cancer subtypes, and with poor 
survival in these cancers.  
CHDH knockdown caused cell cycle arrest in a previous phenotypic screening, but not much 
was known about CHDH and choline metabolism in cancer cells. Therefore we designed a 
detailed experiment where we cultured normal and cancer cells in 13C choline. We found that 
CHDH expression and activity, as shown by betaine labeling from choline, was present in 
cancer cells but not in the non-cancer HMEC cell lines. However, CHDH silencing did not 
affect cell proliferation despite the fact that there was a decrease in betaine labeling, but some 
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hairpins caused cell cycle arrest. The role of betaine in the studied cancer cells is still in 
question, but one possibility is that betaine is advantageous for cells in tumor tissues but has 
lost its function in cell lines. Besides, our choline tracing experiment created opportunities for 
exploring other reactions of choline metabolism. We provide a list of 122 metabolite peaks 
labeled from choline, including several unknown metabolites which suggest previously 
undescribed pathways in human cells.   
4.2 Discussion, reflections and perspectives 
The two main points of focus in this thesis are to describe and understand the biology of 
metabolism across cell cycle phases, and to identify potential candidates that create 
vulnerabilities for cancer cells. Here I present the first large survey of hundreds of metabolite 
abundances and activities in G1 and S-G2-M phases. We present a new method for tracing 
metabolic activities in sorted subpopulations, which in combination with HRLC-MS make 
possible detection and measurement of hundreds of metabolites. This approach is closer to 
single cell metabolomics, but at present is limited by number of cells (around 50 000) required 
to inject in MS in order to obtain good signal from metabolite peaks. Detected peaks were 
carefully curated and checked for false peaks or metabolite fragments, which is extremely 
important for untargeted analysis and aim identifying unknown metabolites. In several cases 
we encountered arginine, choline, and phosphocholine fragments, and many instances of 
phosphocholine polymerization products which were carefully identified and annotated. 
Isotope tracing is an important tool that helps identify fragments by comparing labeling patterns 
between metabolite and fragment. Full scan LC-MS produces a large amount of data which 
requires specialized skills to extract and analyze peaks, becoming a challenge to reproduce 
others’ analysis and store data in a systematic way. 
Isotope tracing is a powerful technique that reflects metabolic activities before separation of 
cells in the dish, tumor or other mixed population. In this way measurement of labeled 
metabolites is affected to a lesser extent by experimental procedures. For the cell cycle studies 
we cultured cells in medium where most nutrients were 13C labeled in order to cover most 
metabolites that are synthesized by cells. Labeled metabolites reflected activities of the 
respective enzymes in G1 and S-G2-M phases. 
Metabolism is very dynamic and easily disturbed by experimental handling that must ensure 
good to minimize leakage of metabolites. Thus, the fluorescent probe or dye that binds to the 
cell sorting marker should either be co-expressed with a cyclic protein in engineered cells, be 
easily incorporated into live cells or bind to a marker that is located at cell surface. A good 
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marker for cell cycle phase separation determines the resolution of the study. DNA staining is 
a good approach for separating G1 and S-G2-M phases because it can be easily applied to almost 
all cell lines since DNA duplicates in S phase, and there are cell permeable dyes like Hoechst-
34580 which we used in our studies. Antibodies that bind to internal cyclic proteins are 
problematic because staining procedures require cell permeabilization. In this regard, 
identification of cyclic cell surface markers in future studies might allow better separation of 
cell cycle phases. DNA staining combined with another cell cycle marker would increase the 
resolution for cell cycle separation. 
Despite challenges for finding a good cell cycle marker, combination of cell sorting with 
isotope tracing and LC-MS provides a less invasive approach as compared to other current 
methods like synchronization with chemicals that block metabolic reactions. Besides, sorting 
allows clean separation while avoiding mixing of cell cycle phases, as opposed to enrichment 
of a cells in a cell cycle phase during synchronization.  
Selecting a good candidate metabolite to invest in follow up experiments is a challenge. To 
increase chances of selecting the right metabolite that is important for cancer cell proliferation, 
we combined metabolomics data, expression level data and phenotypic screening. Difference 
in ornithine labeling between phases, and the fact that ARG2 caused a cell cycle defect in the 
siRNA screening was encouraging for further exploration of this pathway. The knockdown 
experiments gave promising results during short treatment with siRNA, but was difficult to 
apply to specific cell types like normal cells. Validation of these experiments in normal cells 
with induced stable knockouts (CRISPR or shRNA) will be critical. Future ARG2 studies 
might cover two aspects. One aspect is to elucidate the mechanisms that ARG2 silencing 
decrease cancer cell proliferation. It is unclear whether the phenotype observed is due to 
polyamine deprivation. The other aspect is to block ARG2 for sensitizing cancer cells in 
tumors. In a large-scale survey of patient tissue samples, initially we did not find any correlation 
of ARG2 overexpression with any tumor type. However, more careful investigation revealed 
that ER negative and basal subtypes of breast cancers have a higher expression of ARG2. This 
is an important lead for further experiments, which should be directed in these subtypes of 
breast cancer. Targeting ARG2 could be attractive, since ER negative breast cancers are 
difficult to target. Arginine tracing and quantification of ornithine and polyamines in normal 
and tumor tissues can provide useful details about ARG2 as a potential target. 
Findings from this thesis should be encouraging to perform additional studies using tissues 
from specific tumor types. For example, use breast tumors, one might separate normal and 
cancer cells and study their metabolism in G1 and S-G2-M phases. Besides the cell cycle – 
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metabolism scope, in the future will be interesting to study metabolites that cause cancer in a 
more systematic way (as described in Figure 2).  
Overall, this thesis provides a better understanding of metabolism across cell cycle, elucidating 
metabolic activities and relative abundances. The work presented in this thesis is a resource for 
metabolism across the cell cycle data, which can be used as a reference for interesting findings, 
and encourage further exploration. The method of isotope tracing, sorting and LC-MS is also 
a valuable tool that can be used to study metabolomics in different subpopulations. ARG2 is a 
promising target for ER negative and basal subtype of breast cancer. The study of choline 
tracing provides a new avenue for exploration of choline metabolism in normal and cancer 
cells. 
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